New York, USA — Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight
For patients with advanced Dry Age-Related Macular Degeneration, also called geographic atrophy (GA), there is currently no FDA-approved therapy. There are, however, several treatments that are currently in clinical trials. Apl-2, Zimura, Oracea, and others are the drug molecules recently being investigated for the treatment of late-stage dry AMD. Strong Dry Age-related Macular Degeneration pipeline is anticipated to augment the market.
DelveInsight’s ‘Dry Age-related Macular Degeneration Pipeline Insight 2021′ report provides comprehensive global coverage of available, marketed, and pipeline Dry AMD therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the Dry Age-related Macular Degeneration pipeline domain.
Key Takeaways from the Dry Age-related Macular Degeneration Pipeline Report
Request a sample and discover more about the report offerings @ Dry Age-related Macular Degeneration Pipeline Outlook
The Dry Age-related Macular Degeneration pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Dry Age-related Macular Degeneration products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Dry Age-related Macular Degeneration pipeline landscape.
Dry Age-related Macular Degeneration Overview
Age-related Macular Degeneration (AMD) is a degenerative disease of the ocular-posterior segment’s center (the macula lutea) that causes slow degeneration of central vision and severe disability in affected individuals. Clinically, AMD is classified using various methods. One such approach is to categorize the disease as early-stage to late-stage (advanced AMD). Advanced AMD is divided into two types: nonexudative or atrophic AMD (dry AMD) and exudative or neovascular AMD (wet AMD).
Find out more about the disease and recent developments @ Dry Age-related Macular Degeneration Pipeline Assessment
Dry Age-related Macular Degeneration Pipeline Drugs
Drug
Company
Phase
MoA
RoA
Zimura
IVERIC bio
Phase III
Complement C5 inhibitors
Intravitreous
ALK-001
Alkeus Pharmaceuticals
Antioxidants
Oral
GT005
Gyroscope Therapeutics
Phase II
Complement factor I replacements; Gene transference
Subretinal
Risuteganib
Allegro Ophthalmics
Integrin inhibitors
GEM103
Gemini Therapeutics
Complement factor H replacements
CPCB-RPE1
Regenerative Patch Technologies
Phase I/II
Pluripotent stem cell therapies
RPESC RPE 4W
Luxa Biotechnology
Cell replacements
Intraocular
Eyecyte RPE
Eyestem
Preclinical
NA
OLX301A
OliX Pharmaceuticals
RNA interference
EYS809
Eyevensys
Gene transference; Vascular endothelial growth factor A inhibitors
Dry Age-related Macular Degeneration Therapeutics Assessment
The Dry Age-related Macular Degeneration Pipeline report proffers an integral view of the Dry Age-related Macular Degeneration emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the Dry Age-related Macular Degeneration Pipeline Report
Dive deep into rich insights for emerging therapies and assessment, visit @ Dry Age-related Macular Degeneration Emerging Therapies
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Dry Age-related Macular Degeneration: Overview
4.
Pipeline Therapeutics
5.
Late Stage Products (Phase III)
5.1.
Zimura: IVERIC bio
5.2.
ALK-001: Alkeus Pharmaceuticals
6.
Mid Stage Products (Phase II)
6.1.
GT005: Gyroscope Therapeutics
GEM103: Gemini Therapeutics
7.
Early Stage Products (Phase I/II)
7.1.
CPCB-RPE1: Regenerative Patch Technologies
8.
Preclinical Stage Products
8.1.
OLX301A: OliX Pharmaceuticals
8.2.
Eyecyte RPE: Eyestem
9.
Therapeutic Assessment
10.
Inactive Products
11.
Dry Age-related Macular Degeneration Key Companies
12.
Dry Age-related Macular Degeneration Key Products
13.
Dry Age-related Macular Degeneration- Unmet Needs
14.
Dry Age-related Macular Degeneration- Market Drivers and Barriers
15.
Dry Age-related Macular Degeneration- Future Perspectives and Conclusion
16.
Dry Age-related Macular Degeneration Analyst Views
17.
Appendix
18.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight